Soleil Securities Maintains a 'Buy' Rating on Hospira (HSP); We See Upside on Taxotere, Option Value on Gemzar
Tweet Send to a Friend
Soleil Securities maintains a 'Buy' rating on Hospira (NYSE: HSP), PT increased from $61 to $67.
Soleil analyst says, "With ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Soleil analyst says, "With ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
